Healix is Now a National Provider of Trogarzo™ (ibalizumab-uiyk)


SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the first FDA-approved CD-4 detected post-attachment HIV-1 inhibitor.

Trogarzo™ is administered intravenously every 14 days and is used in combination with other antiretroviral drugs.

Consider working with Healix to insource the administration of Trogarzo™ and other therapies for treatment of infections and chronic diseases within your practice.

Healix provides expert management solutions to assist you in establishing or growing an Office Infusion Center (OIC) as a seamless extension of a physician’s practice. Patients are treated under the physician’s direct supervision and are supported by an integrated clinical team of infusion nurses and pharmacists who coordinate patient care, educate patients, admix and administer infusions in the office and at home, and monitor laboratory results.

For more information visit www.healix.net/trogarzo or call 1.866.654.2451.


Healix has helped establish and manage hundreds of infusion centers nationwide since 1989. We support infectious disease physicians, immunologists, gastroenterologists, neurologists, and rheumatologists to fully integrate an OIC within their practice and provide individualized care plans in an ambulatory setting.

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.